We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sensory Medical Gets FDA OK for First Non-Drug RLS Treatment

Sensory Medical Gets FDA OK for First Non-Drug RLS Treatment

May 30, 2014

The FDA last week greenlighted Sensory Medical’s vibrating Relaxis pad for the treatment of patients with primary restless leg syndrome — the first nonpharmacological approach for the painful neurological disorder, which affects about 12  million Americans.

To treat an RLS episode, patients place the low-profile Relaxis pad at the site of discomfort and select a vibration intensity. The device, which can be used in bed, provides 30 minutes of counterstimulation, gradually ramping down intensity and shutting off without waking the patient, the San Clemente, Calif., company says.

RLS symptoms occur primarily while a person is resting, and many patients find their only relief comes from physical movement, which causes sleep interruption and may lead to physical fatigue, impaired mental functioning and emotional stress, according to the National Institute for Neurological Disorders and Stroke.

Medication, including dopaminergic agents used to treat Parkinson’s disease, anticonvulsants, narcotic opioids, muscle relaxants and sleep medications, have been the standard care for RLS. But they pose risks of dependency and, in some cases, may worsen RLS symptoms over time, Sensory Medical says.

The market for RLS treatments is hard to quantify due to there being few RLS-specific drugs, but Sensory Medical spokeswoman Laura Min Jackson estimates it is at least $1 billion for on-label prescriptions.

With U.S. marketing clearance in hand, thecompany is pursuing a CE Mark this year, Jackson says. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.

Medical Devices Submissions and Approvals Commercial Operations

Upcoming Events

  • 13Jul

    FDA Ad and Promo Enforcement Trends: Past, Present and Future

  • 27Jul

    Applying the Lessons of the Pandemic to Your Upcoming Trial

  • 28Jul

    EU-MDR’s Growing Pains: Are You Current with the Latest Developments?

  • 28Jul

    Is Your Product a Drug or Device — and Does It Matter?: A Recent Appeals Court Decision Says It Does

  • 02Aug

    Medical Device Cybersecurity: Understand the Latest Developments

  • 03Aug

    Pharmaceutical Process Validation: Best Practices for Success

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FX Receives FDA Clearance for Its FX V135 Shoulder Arthroplasty Platform

  • FDA Recommends Modified COVID-19 Vaccine Boosters Adapted to Omicron BA.4 and BA.5 Subvariants

  • FDA Approves Foundation Medicine’s Companion Diagnostic for Genentech’s Rozlytrek

  • Novartis Pays $100 Million for Mallinckrodt’s Priority Review Voucher

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing